Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1712339 | 1.00 | CYP2D6 (0.50) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL1964866 | 1.00 | CYP2D6 (0.50) | CYP2D6SRCLMNAMAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL1967435 | 0.98 | KMT2A (0.48) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL10065853 | 0.88 | PTGS2 (0.58) | CYP2D6CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL2628427 | 0.84 | KMT2A (0.45) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL6275744 | 0.84 | KMT2A (0.45) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL6275948 | 0.84 | KMT2A (0.45) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL6966020 | 0.84 | KMT2A (0.45) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL6714743 | 0.83 | FOLH1 (0.55) | CYP2D6SRCLMNAKMT2ACHRM2 | |
| SCHEMBL5427932 | 0.83 | FOLH1 (0.55) | CYP2D6SRCLMNAKMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4092038-A1 | OPIOID AGONIST PEPTIDES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| CN-111187338-B | Modulation of complement activity | RA制药公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20230414732-A1 | COMPOSITIONS OF EMBEDDED EPITOPE RANDOM PEPTIDES (EERP) FOR TREATMENT OF IMMUNE-MEDIATED CONDITIONS, AND METHODS OF USE | PALENA THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-4243834-A2 | COMPOSITIONS OF EMBEDDED EPITOPE RANDOM PEPTIDES (EERP) FOR TREATMENT OF IMMUNE-MEDIATED CONDITIONS, AND METHODS OF USE | Palena Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230279553-A1 | Method for Manufacturing Conductive Pattern-Provided Structure | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-09-07 | — | — | US | disclosed |
| EP-4234758-A1 | METHOD FOR MANUFACTURING CONDUCTIVE PATTERN-PROVIDED STRUCTURE | Asahi Kasei Kabushiki Kaisha (JP) | 2023-08-30 | — | — | EP | disclosed |
| CN-115989341-A | Method for manufacturing structure with conductive pattern | 旭化成株式会社 | 2023-04-18 | — | — | CN | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| EP-4092038-A1 | OPIOID AGONIST PEPTIDES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| WO-2022103673-A2 | COMPOSITIONS OF EMBEDDED EPITOPE RANDOM PEPTIDES (EERP) FOR TREATMENT OF IMMUNE-MEDIATED CONDITIONS, AND METHODS OF USE | FRIDKIS HARELI MASHA (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-05-14 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | CARLING WILLIAM ROBERT | 2009-02-26 | — | — | US | disclosed |
| US-7482354-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-08-09 | — | — | US | disclosed |
| EP-1345918-B1 | 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| EP-0748325-B1 | PROCESS FOR PREPARING [L]- OR [D]-HOMOALANIN-4-YL-(METHYL)PHOSPHINIC ACID AND ITS SALTS BY RACEMIC RESOLUTION | HOECHST SCHERING AGREVO GMBH (DE) | 1999-02-03 | — | — | EP | disclosed |
| EP-0748325-A1 | PROCESS FOR PREPARING [L]- OR [D]-HOMOALANIN-4-YL-(METHYL)PHOSPHINIC ACID AND ITS SALTS BY RACEMIC RESOLUTION | Hoechst Schering AgrEvo GmbH (DE) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995023805-A1 | PROCESS FOR PREPARING [L]- OR [D]-HOMOALANIN-4-YL-(METHYL)PHOSPHINIC ACID AND ITS SALTS BY RACEMIC RESOLUTION | HOECHST SCHERING AGREVO GMBH (DE) | 1995-09-08 | — | — | WO | disclosed |
| EP-0499376-A1 | Precipitation-induced asymmetric transformation of chiral alpha-amino acids and salts thereof | HOECHST CELANESE CORPORATION (US) | 1992-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124605-A1 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors | MAP3K5, MAP3K9, MAP4K2 | CYP2D6 1194/4885SRC 321/4885LMNA 2756/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | CYP2D6 3388/4885SRC 1144/4885LMNA 4788/4885 |
| US-20090054440-A1 | Quinoline derivatives as neurokinin receptor antagonists | TACR2, TACR3, NPY2R | CYP2D6 1735/4885SRC 3538/4885LMNA 2882/4885 |
| US-20070185143-A1 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP3K19 | CYP2D6 1147/4885SRC 293/4885LMNA 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.